Results from a phase 1/2, first-in-human, dose escalation and dose expansion study of an investigational anti-ADAM9 antibody-drug conjugate IMGC936 in patients with advanced solid tumors

被引：0

作者：

Subbiah, V. ^{[1
]}

Falchook, G. ^{[2
]}

Davis, A. A. ^{[3
]}

Wang, J. S. ^{[4
]}

de Miguel, M. ^{[5
]}

Santoro, A. ^{[6
]}

Maur, M. ^{[7
]}

Aljumaily, R. ^{[8
]}

Boni, V. ^{[9
]}

de Speville, B. Doger ^{[10
]}

Sun, Y. ^{[11
]}

Du, Y. ^{[12
]}

Lakshmikanthan, S. ^{[13
]}

Bedse, G. ^{[14
]}

Ward, A. ^{[15
]}

Zweidler-McKay, P. ^{[11
]}

Gandhi, L. ^{[16
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Houston, TX USA

[2] HealthONE, Sarah Cannon Res Inst, Dept Drug Dev, Denver, CO USA

[3] Washington Univ St Louis, Div Oncol, St Louis, MO USA

[4] Florida Canc Specialists Sarah Cannon Res Inst, Drug Dev Unit, Sarasota, FL USA

[5] START Madrid CIOCC HM Sanchinarro, Early Phase Clin Trial Program, Madrid, Spain

[6] Humanitas Univ, Dept Biomed Sci, Humanitas Canc Ctr, IRCCS Humanitas Res Hosp, Milan, Italy

[7] Azienda Osped Univ Policlin Modena, Div Oncol, Modena, Italy

[8] Univ Oklahoma, Sect Hematol Oncol, Stephenson Canc Ctr, Hlth Sci Ctr, Oklahoma City, OK USA

[9] NEXT Madrid Univ Hosp Quironsalud, Oncol Early Drug Dev Unit, Madrid, Spain

[10] START Madrid FJD Hosp Univ Fdn Jimenez Diaz, Early Phase Clin Trials Unit, Madrid, Spain

[11] ImmunoGen Inc, Clin Dev, Waltham, MA USA

[12] ImmunoGen Inc, Biostat, Waltham, MA USA

[13] ImmunoGen Inc, Translat Med, Waltham, MA USA

[14] ImmunoGen Inc, Clin Pharmacol, Waltham, MA USA

[15] MacroGenics Inc, Clin Dev, Rockville, MD USA

[16] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA

来源：

EUROPEAN JOURNAL OF CANCER | 2024年 / 211卷

关键词：

D O I：

10.1016/j.ejca.2024.114703

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PB170

引用

页码：S72 / S73

页数：2

共 50 条

[31] Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors
Joerger, Markus
Calvo, Emiliano
Laubli, Heinz
Lopez, Juanita
Alonso, Guzman
de la Fuente, Elena Corral
Hess, Dagmar
Konig, David
Perez, Vicky Sanchez
Bucher, Christoph
Jethwa, Sangeeta
Garralda, Elena
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (11)
[32] A first-in-human phase 1 dose escalation study of FF-10850 (liposomal topotecan) in patients with advanced solid tumors.
Matulonis, Ursula A.
Janku, Filip
Moser, Justin C.
Fu, Siqing
Wages, David S.
Wheeler, Catherine A.
Mori, Mikinaga
Shimoyama, Susumu
Yamada, Naoki
Subach, Ruth Ann
Cheung, Kin
Madden, Timothy
Maier, Gary
Johansen, Mary
Falchook, Gerald Steven
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[33] First-in-human, phase 1 dose-escalation and dose-expansion study of a RET inhibitor SY-5007 in patients with advanced RET-altered solid tumors
Li, Wei
Wang, Yongsheng
Xiong, Anwen
Gao, Ge
Song, Zhengbo
Zhang, Yiping
Huang, Dingzhi
Ye, Feng
Wang, Qiming
Li, Zhihui
Liu, Jiaye
Xu, Chunwei
Sun, Yinghui
Liu, Xijie
Zhou, Fei
Zhou, Caicun
SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2024, 9 (01)
[34] First-in-human, phase 1, open-label, dose-escalation, dose-expansion study of ADCT901 as monotherapy in patients with select advanced solid tumors
Harvey, R. Donald
Falchook, Gerald Steven
Naqash, Abdul Rafeh
Kim, Joseph W.
Dowlati, Afshin
Le Bruchec, Yvan
Coudert, Isabelle
Ervin-Haynes, Annette L.
Sommerhalder, David
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[35] First-in-Human, Dose Escalation and Expansion Study of MT-6402 in Patients With PD-L1 Expressing Advanced Solid Tumors
Spigel, D. R.
Anand, B.
Carroll, K.
Dekker, J.
Georgy, A.
Hankins, S.
Rethy, A.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1102 - S1102
[36] Final results from phase I, first-in-human, dose escalation study of a first-in-class anti-ILT2 antibody, SAR444881, alone and with pembrolizumab or cetuximab, in patients with advanced solid tumors
Perets, R.
Stemmer, S. M.
Geva, R.
Golan, T.
Fakih, M.
Cohen, J. E.
Lieu, C.
Jin, Z.
Lorusso, P.
Friedman, I.
Hakim, M.
Ziv, D. Haves
Hashmueli, S.
Mandel, I.
Ben Moshe, T.
Crawford, N.
Abbadessa, G.
Perez, R.
Wu, M.
Borad, M.
ANNALS OF ONCOLOGY, 2024, 35 : S675 - S675
[37] A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody-drug conjugate, in patients with breast cancer and other advanced solid tumors
Rosen, Lee S.
Wesolowski, Robert
Baffa, Raffaele
Liao, Kai-Hsin
Hua, Steven Y.
Gibson, Brenda L.
Pirie-Shepherd, Steven
Tolcher, Anthony W.
INVESTIGATIONAL NEW DRUGS, 2020, 38 (01) : 120 - 130
[38] Dose escalation and expansion results from the phase I study of F0024, a trophoblast cell-surface antigen 2 (TROP2) antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors.
Du, Yiqun
Meng, Yanchun
Wang, Jingfen
Wang, Ying
Wu, Fan
Chen, Yu
Chen, Lilin
Qing, Lihua
Qiao, Yaya
Liu, Kezhen
Sun, Wenyi
Li, Xiaowen
Zhang, Jian
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[39] Results From First-in-Human Phase I Dose-Escalation Study of a Novel Bicycle Toxin Conjugate Targeting EphA2 (BT5528) in Patients With Advanced Solid Tumors
Bashir, Babar
Wang, Judy S.
Falchook, Gerald
Fontana, Elisa
Arkenau, Hendrik-Tobias
Carter, Louise
Galot, Rachel
Basu, Bristi
Greystoke, Alastair
Subbiah, Vivek
Richardson, Debra L.
Orr, Hanna
Bennett, Gavin
Sharma, Rajiv
Xu, Hongmei
Paganoni, Paola
Xu, Cong
Campbell, Carly
McKean, Meredith
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (29)
[40] First-in-Human Study of OBI-999, a Globo H-Targeting Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors
Tsimberidou, Apostolia Maria
Vo, Henry Hiep
Beck, Jennifer
Shia, Chi-Sheng
Hsu, Pei
Pearce, Tillman E.
JCO PRECISION ONCOLOGY, 2023, 7

← 1 2 3 4 5 →